- About EAS
|The EAS-FH Studies Collaboration (FHSC)|
EAS FH Studies Collaboration - a global call to action
Familial Hypercholesterolaemia (FH) represents a major global health problem because it is common, widely underdiagnosed, undertreated and as a result often fatal. The consequences of FH in the form of premature atherosclerosis and cardiovascular events are potentially preventable but require effective initiatives and policies to reduce the current burden of disease.
To address these issues investigators from all round the world have come together under the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) to initiate a global call to take action. These include raising awareness and encouraging the development of programmes, initiatives and policies specifically focused on FH by joining efforts from healthcare providers, patients organizations, policy makers and the entire medical community. This call to action is described in an article published in Atherosclerosis.
The FHSC currently involves lead investigators from over 50 countries and other investigators are expected will join as the project is developed, resulting in a global network that aims to generate large-scale robust novel data to ultimately inform future guidelines on the management of FH.
The article describes an overview of the present situation relating to FH in different regions around the world and provides a framework for further work that needs to be undertaken to reduce the impact of FH and the global burden of the disease.
Read the article
Familial Hypercholesterolaemia: A global call to arms, Vallejo-Vaz, Antonio J. et al., Atherosclerosis. http://dx.doi.org/10.1016/j.atherosclerosis.2015.09.021
The EAS-FH Studies Collaboration (FHSC) is a global initiative led by Prof Kausik Ray (Imperial College London, UK) and an international steering committee comprising Prof Alberico L. Catapano (Italy); Dr. Tomas Freiberger (Czech Republic); Prof John Kastelein, Prof G.Kees Hovingh (Netherlands); Prof Pedro Mata (Spain); Dr Handrean Soran (UK); Prof Gerald Watts (Australia); Prof Frederick Raal (South Africa) and Prof Raul Santos (Brazil).
The mission of the EAS-FHSC is to empower the medical & global community to seek change in their respective countries or organizations regarding how FH is detected and managed, with a view to promoting early diagnosis and more effective treatment of this condition. Through international collaboration of stakeholders we aim to generate large scale robust data on how FH is detected, managed and the clinical consequences of current practice on outcomes.
Furthermore, we will work with all stakeholders including patient’s organizations to ensure that these state-of-the-art information are utilized to close gaps in knowledge and/or improve clinical practice for our FH patients.
01/02/2017 » 01/05/2017
Abstract submission for the 40th Annual Scientific ELC meeting opens!
11/03/2017 » 14/03/2017
Immuno-Metabolic Mechanisms of Atherosclerosis